Investor Relations
Proposed Acquisition of TxCell
French - Projet de note d’information
English - Draft offer prospectus
Communique de depot du projet de note d’information
Press release on the filing of the offeror’s draft prospectus
English – 10/30/2018 - TxCell-Sangamo - Offeror's prospectus
French – 10/30/2018 - TxCell-Sangamo - Note d'information
French – 10/30/2018 - TxCell-Sangamo - Note en réponse(Target’s prospectus)
French – 10/31/2018 – TxCell-Sangamo - Communiqué de mise à disposition – Initiateur
French – 10/31/2018 -- TxCell-Sangamo - Communiqué de mise à disposition – Cible
French – 10/31/2018 – TxCell-Sangamo - Autres informations TxCell
French – 10/31/2018 -- TxCell-Sangamo - Autres informations Sangamo
Corporate Profile
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in hemophilia A and hemophilia B, lysosomal storage disorders MPS I and MPS II, as well as beta thalassemia. Sangamo has an exclusive, global collaboration and license agreement with Kite, a Gilead company, for engineered cell therapies for oncology, with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington’s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including MilliporeSigma and Dow AgroSciences.
Stock Quote
Copyright West LLC. Minimum 15 minutes delayed.